|Source:||The roots of Panax ginseng C. A. Mey.|
|Biological Activity or Inhibitors:||1. Ginsenoside Rk3 and Rh4 could have a role in treating inflammatory diseases.
2. Ginsenoside Rk3 is often used as a major ingredient of the compound preparation for ischemic heart diseases.
|Solvent:||DMSO, Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||1.6106 mL||8.0528 mL||16.1057 mL||32.2113 mL||40.2641 mL|
|5 mM||0.3221 mL||1.6106 mL||3.2211 mL||6.4423 mL||8.0528 mL|
|10 mM||0.1611 mL||0.8053 mL||1.6106 mL||3.2211 mL||4.0264 mL|
|50 mM||0.0322 mL||0.1611 mL||0.3221 mL||0.6442 mL||0.8053 mL|
|100 mM||0.0161 mL||0.0805 mL||0.1611 mL||0.3221 mL||0.4026 mL|
Evid Based Complement Alternat Med. 2013;2013:690190.
|Ginsenoside RK3 Prevents Hypoxia-Reoxygenation Induced Apoptosis in H9c2 Cardiomyocytes via AKT and MAPK Pathway.[Pubmed: 23935671 ]|
|Ginsenoside Rk3 (RK3) is reportedly present in the processed Radix notoginseng that is often used as a major ingredient of the compound preparation for ischemic heart diseases. This study aimed to investigate the possible protective effect of Ginsenoside Rk3 against hypoxia-reoxygenation (H/R) induced H9c2 cardiomyocytes damage and its underlying mechanisms. Our results showed that Ginsenoside Rk3 pretreatment caused increased cell viability and decreased levels of LDH leakage compared with the H/R group. Moreover, Ginsenoside Rk3 pretreatment inhibited cell apoptosis, as evidenced by decreased caspase-3 activity, TUNEL-positive cells, and Bax expression, as well as increased Bcl-2 level. Further mechanism investigation revealed that Ginsenoside Rk3 prevented H9c2 cardiomyocytes injury and apoptosis induced by H/R via AKT/Nrf-2/HO-1 and MAPK pathways. These observations indicate that Ginsenoside Rk3 has the potential to exert cardioprotective effects against H/R injury, which might be of great importance to clinical efficacy for AMI treatment.|
Biol Pharm Bull. 2011;34(6):898-900.
|Anti-complementary ginsenosides isolated from processed ginseng.[Pubmed: 21628891]|
|As part of an ongoing search for immunomodulatory components aimed at the anti-complementary effect, ginsenosides isolated from processed ginseng were found to have inhibitory activity on complement activation through classical pathways. Activity-guided fractionation was used to isolate four ginsenosides, namely Rg6, F4, Rk3, and Rh4. Ginsenoside Rk3 and Rh4 had a 3 fold higher inhibition activity than rosmarinic acid which was used as a positive control while ginsenoside Rg6 and F4 showed only mild effects similar to that of the positive control. The results suggest that the activity of the corresponding ginsenosides may be increased by the glycosyl moiety at the C₆ position rather than the double bond conformation at C20, and Ginsenoside Rk3 and Rh4 could have a role in treating inflammatory diseases.|